164 related articles for article (PubMed ID: 27815724)
1. Observational study of multiple myeloma in Latin America.
Hungria VT; Maiolino A; Martinez G; Duarte GO; Bittencourt R; Peters L; Colleoni G; Oliveira LC; Crusoé E; Coelho ÉO; Pasquini R; Magalhães SM; Nunes R; Neto JV; Faria RM; Souza M; Hamerschlak N; Flantl D; Navarro JR; Conte G; Gomez-Almaguer D; Ruiz-Argüelles G; Durie BG;
Ann Hematol; 2017 Jan; 96(1):65-72. PubMed ID: 27815724
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016.
de Moraes Hungria VT; Martínez-Baños DM; Peñafiel CR; Miguel CE; Vela-Ojeda J; Remaggi G; Duarte FB; Cao C; Cugliari MS; Santos T; Machnicki G; Fernandez M; Grings M; Ammann EM; Lin JH; Chen YW; Wong YN; Barreyro P
Br J Haematol; 2020 Feb; 188(3):383-393. PubMed ID: 31392724
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.
Hungria VT; Crusoé EQ; Maiolino A; Bittencourt R; Fantl D; Maciel JF; Pessoa de Magalhaes RJ; Almeida MS; Cury P; Hisgashi F; Peres AL; Chiattone CS
Ann Hematol; 2016 Jan; 95(2):271-8. PubMed ID: 26518211
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Tietsche de Moraes Hungria V; Chiattone C; Pavlovsky M; Abenoza LM; Agreda GP; Armenta J; Arrais C; Avendaño Flores O; Barroso F; Basquiera AL; Cao C; Cugliari MS; Enrico A; Foggliatto LM; Galvez KM; Gomez D; Gomez A; de Iracema D; Farias D; Lopez L; Mantilla WA; Martínez D; Mela MJ; Miguel CE; Ovilla R; Palmer L; Pavlovsky C; Ramos C; Remaggi G; Santucci R; Schusterschitz S; Sossa CL; Tuna-Aguilar E; Vela J; Santos T; de la Mora O; Machnicki G; Fernandez M; Barreyro P
J Glob Oncol; 2019 Nov; 5():1-19. PubMed ID: 31774711
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
6. The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan.
Huang TC; Chen JH; Wu YY; Chang PY; Dai MS; Chao TY; Kao WY; Chen YC; Ho CL
Ann Hematol; 2015 Jan; 94(1):107-15. PubMed ID: 25047657
[TBL] [Abstract][Full Text] [Related]
7. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study.
Peña C; Riva E; Schutz N; Tarín-Arzaga L; Martínez-Cordero H; Bove V; Osorio R; Chandía M; Beltrán C; Schulz J; Cardemil D; Contreras C; Vergara CG; Donoso J; Espinoza M; La Rocca G; López-Vidal H; León P; Rojas Hopkins C; Soto P; Aranda S; Torres V; Roa M; Ochoa P; Duarte PJ; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García C; Fernández V; Ramirez J; Molina A; Pacheco M; Mite A; Reyes I; Sabando B; Ramírez F; Sossa C; Abello V; Idrobo H; Galvez Cardenas KM; Saavedra D; Quintero G; Gazitúa R; Gaviria L; Gomez R; Osuna M; Henao-Uribe A; Cantú-Martínez O; Gómez-Almaguer D; García-Navarrete YI; Cruz-Mora A; Cantero-Fortiz Y; Ruiz-Argüelles GJ; Fantl D
Leuk Lymphoma; 2020 Dec; 61(13):3112-3119. PubMed ID: 32844699
[TBL] [Abstract][Full Text] [Related]
8. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries.
Hungria VTM; Lee JH; Maiolino A; de Queiroz Crusoe E; Martinez G; Bittencourt R; Duarte GO; Fantl DB; Navarro JR; Conte G; Gomez-Almaguer D; Ruiz-Argüelles GJ; Kim K; Shimizu K; Chen W; Huang SY; Chng WJ; Chim CS; Nawarawong W; Durie B
Ann Hematol; 2019 Apr; 98(4):941-949. PubMed ID: 30729281
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma in Latin America.
Gómez-Almaguer D; de Moraes Hungria VT
Hematology; 2022 Dec; 27(1):928-931. PubMed ID: 36000971
[TBL] [Abstract][Full Text] [Related]
10. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
11. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
12. Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre.
Fernyhough LJ; Hock BD; Taylor J; Pearson J; Ganly P
Intern Med J; 2013 Feb; 43(2):130-7. PubMed ID: 22530659
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
14. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
15. Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study.
Abello V; Mantilla WA; Idrobo H; Sossa CL; Salazar LA; Pena A; Herrera JM; Guerrero P; Espinosa D; Quintero-Vega GE; Munevar I; Galvez K; Henao A; Gómez R; Saavedra JD; Gaviria LM; Osuna M; Mateos MV
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e405-e413. PubMed ID: 35042679
[TBL] [Abstract][Full Text] [Related]
16. The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.
Lee HS; Min CK; Lee JJ; Kim K; Kim SJ; Yoon DH; Eom HS; Lee H; Lee WS; Shin HJ; Lee JH; Park Y; Jo JC; Do YR; Mun YC; Lee MH;
Ann Hematol; 2016 May; 95(6):911-9. PubMed ID: 27052989
[TBL] [Abstract][Full Text] [Related]
17. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Krejci M; Scudla V; Tothova E; Schutzova M; Koza V; Adam Z; Krivanova A; Pour L; Buchler T; Sandecka V; Kralova D; Zahradova L; Vorlicek J; Mayer J; Hajek R
Clin Lymphoma Myeloma; 2009 Dec; 9(6):436-42. PubMed ID: 19951883
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
